Benzinga | Jun 4, 2021 08:03AM EDT

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

* Encouraging activity signals from the combination of efti and avelumab with a response rate of 41.7% in different solid tumours (DCR 50%) acc. to RECIST 1.1

* No selection of patients for immunogenic markers (e.g. PD-L1 expression levels, MSI high or TMB)

* 9 out of 12 patients still alive

* Deep and durable responses also in patients with low or no PD-L1 expression and typically IO insensitive indications like gastroesophageal or cervical cancer which typically do not respond to immune checkpoint therapy

* Continued good safety profile and promising activity signals warrant further clinical evaluation